Search Results
Results for: NOVARTIS (Save this search)
Number of Results: 129
Novartis Closes USD 1.575bn Acquisition of IFM Tre
13 May 2019 - Switzerland-based biopharmaceutical company Novartis has closed the acquisition of Massachusetts, US-based immune system-focussed biopharmaceutical company IFM Therap...

NOVARTIS CLOSES USD 1.575BN ACQUISITION OF IFM TRE
Switzerland-based biopharmaceutical company Novartis has closed the acquisition of Massachusetts, US-based immune system-focussed biopharmaceutical company IFM Therapeutics, the co...

Novartis to Acquire IFM Tre in Deal Valued at USD 1.575bn
3 April 2019 - Switzerland-based biopharmaceutical company Novartis has agreed to acquire Massachusetts, US-based immune system-focussed biopharmaceutical company IFM Therapeutics,...

NOVARTIS TO ACQUIRE IFM TRE IN DEAL VALUED AT USD 1.575BN
Switzerland-based biopharmaceutical company Novartis has agreed to acquire Massachusetts, US-based immune system-focussed biopharmaceutical company IFM Therapeutics, the company sa...

SECURA BIO ACQUIRES RIGHTS TO FARYDAK FROM NOVARTIS
Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating multiple myeloma, t...

Secura Bio Acquires Rights to Farydak from Novartis
14 March 2019 - Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating mul...

Clinigen to Acquire US Rights to Cancer Drug Proleukin
19 February 2019 - UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights t...

CLINIGEN TO ACQUIRE US RIGHTS TO CANCER DRUG PROLEUKIN
UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights to Proleukin (a...

Eyevance Pharmaceuticals Acquires Flarex from Novartis
26 October 2018 - US-based pharmaceutical company Eyevance Pharmaceuticals has acquired Flarex (fluorometholone acetate ophthalmic suspension) 0.1% from Swiss drugmaker Novartis AG...

You can compare news articles by clicking on the tick buttons
1   2   3   4   5   6   7   8   9   10   11   12   13   >